CJC-1295 ipamorelin oral products have no published human absorption data. A capsule, tablet, troche, or liquid held under the tongue has not been shown to deliver either peptide into the bloodstream in a reliable amount. The human CJC-1295 research used injections under the skin. The main human ipamorelin drug-level study used infusions into a vein. If avoiding needles is the goal, the honest answer is that a pill has not been shown equivalent.
CJC-1295 and ipamorelin are peptides, meaning short chains of amino acids. That structure is central to why the route matters.
Why CJC-1295 ipamorelin oral absorption is doubtful
The stomach and small intestine are built to take proteins and peptides apart. Acids unfold them. Digestive enzymes cut the bonds between their amino acids. Any intact peptide that survives must still cross the gut wall to reach the blood.
That last step is difficult because peptides tend to be larger and more water-loving than ordinary pill ingredients. Bioavailability, the share of a dose that reaches the bloodstream intact, is often below 1% for peptide and protein medicines without purpose-built delivery technology. A 2025 review of oral peptide delivery describes the three main barriers: digestive breakdown, poor passage through the intestinal lining, and instability in the gut.
This does not mean every peptide must always be injected. It means a successful pill needs specific engineering and human testing. An ordinary capsule does not become an effective delivery system simply because the label names a peptide.
What the human studies actually used
The route evidence is clear, even though it is limited. In two small randomized trials published in 2006, healthy adults received long-acting CJC-1295 by subcutaneous injection, meaning into the tissue under the skin. Researchers measured drug levels, growth hormone, and IGF-1, a downstream hormone marker. They did not test a pill, troche, or sublingual liquid (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006).
That study also used CJC-1295 with DAC, an attachment that helps the peptide bind to a blood protein and remain in circulation for days. It does not establish absorption for the shorter-acting form used in many blends. What “no DAC” means explains that form distinction without treating the names as interchangeable.
The 1999 healthy-volunteer ipamorelin study used five 15-minute intravenous infusions, meaning the peptide went directly into a vein. It measured a growth-hormone response and an approximately two-hour terminal half-life, the time for the blood level to fall by half near the end of its decline. It did not test swallowing or mouth absorption (Gobburu et al., Pharmaceutical Research, 1999).
A separate 2015 anti-doping study gave ipamorelin through the nose to one volunteer and measured the drug and its breakdown products in urine. It tested detection after a nasal dose, not oral or sublingual bioavailability (Semenistaya et al., Drug Testing and Analysis, 2015).
The broader CJC-1295 and ipamorelin evidence explains why the two molecules are paired. That mechanism does not answer whether either survives an oral route.
A troche is not the same as a swallowed pill
A troche is a medicine designed to dissolve slowly in the mouth. Sublingual means it is intended to cross the tissue under the tongue. Both try to avoid some digestion, but only the portion that actually crosses the mouth lining escapes the gut. The rest mixes with saliva and is swallowed.
No peer-reviewed human study has established the bioavailability of a CJC-1295/ipamorelin troche, rapid-dissolve tablet, or sublingual liquid. “Dissolves in the mouth” describes what the dosage form does. It does not tell anyone how much intact peptide reaches the blood, how consistent that amount is, or whether it produces the same exposure as an injection.
There is a useful historical clue on the ipamorelin side. Researchers created NN703, a different molecule derived from ipamorelin, specifically to make an orally active growth-hormone secretagogue. Animal testing found oral absorption for NN703, not for ipamorelin itself (Hansen et al., European Journal of Endocrinology, 1999). Borrowing ipamorelin's chemical family does not make the two drugs interchangeable.
Where sermorelin tablets fit
Sermorelin is a related growth-hormone-releasing peptide, so it comes up when someone wants a tablet instead. It is a separate molecule, not oral CJC-1295. Its oral evidence has the same important gap.
The sermorelin tablets evidence guide separates swallowed tablets from mouth-dissolving products and finds no reliable human absorption study for either route. Promise's current sermorelin product is an injectable vial, so the comparison is between two prescribed injectable options, not an evidence-backed tablet and an injection.
What an online “pill” may actually mean
The word pill is often doing too much work. It may refer to a capsule intended to be swallowed, a pressed tablet that dissolves quickly, or a troche intended to sit against the cheek or under the tongue. Those are different routes with different unanswered questions.
The product title also cannot prove what is inside. The useful details are the exact active ingredients, their amounts, the intended route, who prescribed the preparation, which licensed pharmacy dispensed it, and whether that exact formulation has human absorption data. A supplement that borrows the peptide names but lists herbs or amino acids is not CJC-1295 or ipamorelin.
As of September 9, 2026, the day this article was written, an FDA warning letter dated August 24, 2026 named an ipamorelin-containing peptide blend and bacteriostatic water sold beside it as unapproved drugs. The letter concerned products marketed for injection, not an oral CJC-1295/ipamorelin study. Its relevance here is narrower: a laboratory-use label or polished product name does not establish lawful dispensing, verified contents, or a tested route.
What a provider can actually prescribe through Promise
Promise's CJC-1295/ipamorelin product is a compounded injectable vial. Compounded means a licensed pharmacy prepares the medication for an individual prescription. It is not a pill, tablet, or troche, and a format sold elsewhere should not be assumed equivalent.
CJC-1295 and ipamorelin are not FDA-approved for any use, and the compounded blend offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
A licensed provider reviews every request, and not everyone qualifies. If the blend is prescribed, the provider sets the dose and schedule for that exact formulation; the CJC-1295/ipamorelin dosing guide explains how those decisions are made without turning study methods into instructions.
Questions that make the route clear
A trustworthy conversation can answer four plain questions: Is the product swallowed, held in the mouth, or injected? What evidence measures absorption for that exact route? Does the label identify both peptides and the form of CJC-1295? Who is accountable for prescribing, dispensing, and follow-up?
If the only answer is that a product “bypasses digestion,” the central question is still open. How much intact medication reaches the bloodstream, and was that amount measured in people? For oral CJC-1295/ipamorelin, no published human study supplies that number.